Table 2:
Recent Trials Involving Combination Immunotherapy in Metastatic Clear Cell RCC
| CheckMate 214 | Nivolumab + Ipilimumab | 1096 | Nivolumab + Ipilimumab 42%, Sunitnib 27% |
| CheckMate 9ER | Nivolumab + Cabozantinib | 651 | Nivolumab + Cabozantinib 55.7%, Sunitinib 27.1% |
| CLEAR | Pembrolizumab + Lenvatinib | 1069 | Pembrolizumab + Lenvatinib 71%, Everolimus + Lenvatinib 53.5%, Sunitinib 36.1% |
| IMotion151 | Atezolizumab + Bevazicumab | 915 | Atezolizumab + Bevazicumab 37%, Sunitinib 33% |
| Javelin Renal 101 | Avelumab + Axitinib | 886 | Avelumab + Axitinib 51.4%, Sunitinib 25.7% |
| KeyNote 426 | Pembrolizumab + Axitinib | 861 | Pembrolizumab + Axitinib 59.3%, Sunitinib 35.7% |
ORR = objective response rate